Get started today

Medical Cannabis in Treatment of Chronic Pain (Part 1)

This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.

About this module:

In this presentation, you will learn about the three main pain pathways (peripheral, ascending and descending), the role of the endocannabinoid system including CB1 and CB2 receptor signaling in pain modulation, and the mechanisms by which cannabinoids and terpenoids effect antinociceptive actions. Scientific studies which provide evidence of efficacy of cannabis and cannabinoids in relation to chronic pain and the potential role of medicinal cannabis in relation to opioid use and the opioid problem is also examined. 

This presentation is suitable for healthcare practitioners and those with a background in biomedical sciences. It assumes a knowledge of the endocannabinoid system and medicinal cannabis pharmacodynamics.
Learning Outcomes

At the end of this module, learners will be able to:

  • Describe the different pain pathways. 
  • Describe how the endocannabinoid system is involved in pain modulation.
  • Describe the antinociceptive effects mechanisms of action of cannabinoids and terpenoids. 
  • Debate the level of scientific evidence of efficacy for medicinal cannabis in the treatment of chronic pain.
  • Argue the risks and benefits for the use of medicinal cannabis with opioids.
MEET THE INSTRUCTOR

Dr Jeffrey Hergenrather

Professor Kylie O’Brien PhD is an Adjunct Professor at Torrens University. She has a strong academic career in the fields of Chinese medicine, integrative medicine and, after a career change in 2000; medicinal cannabis. She has worked for the Victorian Department of Human Services, and held senior leadership roles in the university and private education sector. An internationally recognised expert in Chinese medicine and integrative medicine, she has published extensively, including a book on integrative oncology (US: Springer, 2017). Kylie’s second book – on mental health and medicinal cannabis – is due for publication in 2020. She is a member of the TGA Advisory Committee for Complementary Medicines and a TEQSA Expert Panel.

Kylie has been leading doctor education on medicinal cannabis in Australia since 2018. Her courses were the first to receive RACGP Category 1 CPD accreditation. She also set up the pathway via the National Institute of Integrative Medicine Ethics Committee for doctors to apply to become authorised prescribers of medicinal cannabis under the TGA’s Authorised Prescriber Scheme.

Featured links

Connect with us

Created with